ArticleOncotarget2017
Dihydroartemisinin inhibits EMT induced by platinum-based drugs via Akt-Snail pathway.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Cystatin SA attenuates gastric cancer cells growth and increases sensitivity to oxaliplatin via PI3K/AKT signaling pathway.Journal of cancer research and clinical oncology · 2024Article
- Repurposing artemisinins as neuroprotective agents: a focus on the PI3k/Akt signalling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Cocktail ofFrontiers in pharmacology · 2022Article
- Dihydroartemisinin as a Sensitizing Agent in Cancer Therapies.OncoTargets and therapy · 2021Review
- Artemisinin induced reversal of EMT affects the molecular biological activity of ovarian cancer SKOV3 cell lines.Oncology letters · 2019Article
- More than anti-malarial agents: therapeutic potential of artemisinins in neurodegeneration.Neural regeneration research · 2019Review
- Protopanaxadiol inhibits epithelial-mesenchymal transition of hepatocellular carcinoma by targeting STAT3 pathway.Cell death & disease · 2019Article
- ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance.Cell death & disease · 2019Article
- Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway.EBioMedicine · 2018Article
- Co-delivery of dihydroartemisinin and docetaxel in pH-sensitive nanoparticles for treating metastatic breast cancerRSC advances · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artemisinin and its derivatives exhibit a high activity against a range of cancer cell types both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.